🧪 Meet BioNucleus Briefing: Biotech News You'll Actually Enjoy 📩
Would you like to be featured in our newsletter🔥 and get noticed, QUICKLY 🚀? Simply reply to this email or send an email to editor@digitalhealthbuzz.com, and we can take it from there.
We spend most of our time here on digital health, health IT, and the startups reshaping care. But the sharpest people in our world know digital health doesn't live in a vacuum — what happens in biotech and pharma shapes everything downstream: the therapies, the data, the deals, and the next breakout company.
That’s exactly why we want to put a new read on your radar: BioNucleus Briefing.
It calls itself “the only biotech newsletter you’ll actually enjoy reading” — and honestly, the claim holds up. BioNucleus Briefing distills the week’s biggest life science headlines into a sharp, skimmable email you can finish in about five minutes, sent every Tuesday and Thursday, completely free.
Take their recent edition, “GLP-1 Hits Happy Hour” — covering how Altimmune’s obesity drug is cutting heavy-drinking days, Freenome’s fresh FDA win, and mosquitoes redrawing the infectious-disease map. That’s the kind of context that makes you sound like the go-to expert the next time biotech comes up in a meeting. If that’s your kind of read, it’s worth a look.
Why we think you’ll love it:
Cut through the noise — the week’s biggest life science stories, distilled.
Look sharper at work — the insights that actually matter, minus the jargon.
Save time (and brain cells) — 5 minutes, twice a week, and you’re ahead of the funding news, trends, and industry moves.
More than 1,400 biotech and pharma professionals are already on the list. If you live anywhere near the intersection of health and technology, subscribing is an easy yes.
👉 Subscribe to BioNucleus Briefing — it’s free
P.S. It’s free, it’s twice a week, and it takes five minutes. Worst case, you unsubscribe. Best case, you’re the smartest person in the room by Thursday. Give it a try.